Milestone Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:MIST) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Total assets 82.71 M75.5 M61.88 M47.42 M87.75 M Total liabilities 58.69 M62.35 M68.01 M65.16 M67.25 M Total equity 24.01 M13.15 M6.1 M17.7 M20.5 M Total liabilities & shareholders' equities 82.71 M75.5 M61.88 M47.42 M87.75 M Total debt ————— Net debt —————

뉴스

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)

Aptar, 새로운 PSVT 치료제 전달 나잘 스프레이 시스템

Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST)

마일스톤 파마슈티컬스, FDA 승인에 TD Cowen "매수"로 상향

Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment - Slideshow (NASDAQ:MIST) 2025-12-15

Milestone stock soars after FDA approves first self-administered PSVT spray

FDA, 최초 자가 투여 PSVT 스프레이 승인 후 Milestone 주가 급등

Why Is Milestone Pharmaceuticals Stock Skyrocketing Monday? - Milestone Pharmaceuticals (NASDAQ:MIST)